<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03167281</url>
  </required_header>
  <id_info>
    <org_study_id>00058518</org_study_id>
    <nct_id>NCT03167281</nct_id>
  </id_info>
  <brief_title>Early Intrapleural TPA Instillation Versus Late</brief_title>
  <acronym>ELEVATE</acronym>
  <official_title>Early Intrapleural TPA Instillation Versus Late</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prisma Health-Midlands</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prisma Health-Midlands</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chest tubes are used for air or fluid removal from the pleural space. When a chest tube is&#xD;
      placed, it can be hard for the fluid to drain.Tissue plasminogen activator (tPA) and DNase&#xD;
      are given through the chest tube to help with draining the fluid. We are doing this research&#xD;
      to see if early addition of tPA-DNase immediately after chest tube placement will help with&#xD;
      better fluid draining.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the timing and efficacy of early administration and&#xD;
      late administration of t-PA/DNase via thoracostomy (n=60). Patients will be identified from&#xD;
      the Intensive Care Unit, Coronary Care Unit, and wards/stepdown units. Prior to chest tube&#xD;
      placement, patients will be randomized to one of the two treatment arms (early use of&#xD;
      t-PA-DNase verus late use of t-PA-DNase). Route of administration will be via their&#xD;
      thoracostomy tube over a period of three days twice daily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of adequate recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Actual">March 10, 2021</completion_date>
  <primary_completion_date type="Actual">March 10, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chest tube removal</measure>
    <time_frame>7 days</time_frame>
    <description>Time to chest tube removal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluid drainage</measure>
    <time_frame>3 days</time_frame>
    <description>Volume of fluid drained after each tPA and DNase instillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for other interventions</measure>
    <time_frame>4 days</time_frame>
    <description>Post tPA/DNase administration, the need for other interventions, such as surgery or additional chest tube, will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge</measure>
    <time_frame>3 weeks</time_frame>
    <description>Time to discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Tissue Plasminogen Activator</condition>
  <arm_group>
    <arm_group_label>tPA and DNase</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily 24-48 hours after chest tube placed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early tPA and DNase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily with initial administration occurring at chest tube placement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>early tPA and DNase</intervention_name>
    <description>Early addition of tPA and DNase (immediately at chest tube placement) versus later (24-48 hours) after chest tube placement.</description>
    <arm_group_label>Early tPA and DNase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients, age 18 years or older&#xD;
&#xD;
          -  Patients with an indication for a thoracostomy tube placement for a pleural effusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients that require a thoracostomy tube for a pneumothorax&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Sensitivity to t-PA, or DNase&#xD;
&#xD;
          -  Patients taking carbamazepine or nitroglycerin&#xD;
&#xD;
          -  Lung volume reduction surgery on side of pleural effusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rohan Mankikar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prisma Health-Midlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palmetto Health Richland</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://scresearch.org/studies/search?utf8=%E2%9C%93&amp;q=Mankikar&amp;commit=GO</url>
    <description>South Carolina Research Studies Directory</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2017</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prisma Health-Midlands</investigator_affiliation>
    <investigator_full_name>Dr. Rohan Arya</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Chest tube</keyword>
  <keyword>Thoracostomy</keyword>
  <keyword>Pleural Diseases</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Pneumothorax</keyword>
  <keyword>Thoracic Surgery</keyword>
  <keyword>Deoxyribonucleases</keyword>
  <keyword>Fibrinolytic Agents</keyword>
  <keyword>Drainage</keyword>
  <keyword>Pleural Effusion</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

